Intravitreal injection versus medical treatment for acute CSR

Central serous chorioretinopathy (CSCR) is a condition occurring in young adults, especially males in their twenties to fifties, who exhibit acute or subacute central visual loss or distortion. It is an idiopathic disorder characterized by a localized serous detachment of the sensory retina at the macula secondary to leakage from the choriocapillaris in association with retinal pigment dysfunction. Different treatment options are available including observation, photodynamic therapy, laser photocoagulation, micropulse diode laser and intravitreal anti VEGF agents. So, this study is designed to evaluate the efficacy and safety of intravitreal ranibizumab or aflibercept versus medical therapy with oral spironolactone for treatment of patients with acute central serous chorioretinopathy.